Aurinia and Lonza Join to Produce Voclosporin for Phase 3 Lupus Nephritis Trial, Possible Market Use
Aurinia Pharmaceuticals and Lonza have entered into a long-term manufacturing agreement over the active pharmaceutical ingredient (API) in voclosporin, Aurinia’s investigative drug for diseases that include lupus nephritis (LN). The agreement aims toward providing an eventual commercial supply of voclosporin, and includes its use in an upcoming and possibly pivotal clinical trial in LN…